| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/31/2012 | US8105774 Using peroxisome proliferator-activated receptor gamma, coactivator 1 beta (PGC-1Beta) as tool to identify modulators for treatment of free radical associated disorders |
| 01/31/2012 | US8105599 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor |
| 01/31/2012 | US8105580 Methods of using adipose derived stem cells to promote wound healing |
| 01/31/2012 | CA2550373C Anti-hypercholesterolemic compounds |
| 01/31/2012 | CA2516698C Novel transcriptional factor, process for producing the same and use thereof |
| 01/31/2012 | CA2504718C Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
| 01/26/2012 | WO2012012667A2 Methods and compositions for modification of a hla locus |
| 01/26/2012 | WO2012012642A1 Tricyclic compounds and methds of making and using same |
| 01/26/2012 | WO2012012460A1 Stable glucagon formulations for the treatment of hypoglycemia |
| 01/26/2012 | WO2012012370A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | WO2012012278A2 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | WO2012011882A1 A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases |
| 01/26/2012 | WO2012011752A2 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity |
| 01/26/2012 | WO2012011707A2 Substituted pyridinone derivatives and methods for manufacturing the same |
| 01/26/2012 | WO2012011592A1 Heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011591A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011174A1 Lipid metabolism improving agent, agent for enhancing lipid metabolism improving action, anti-obesity agent, and agent for enhancing anti-obesity action |
| 01/26/2012 | WO2012011081A1 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics |
| 01/26/2012 | WO2012010977A2 Single daily dosage form for prevention and treatment of metabolic syndrome |
| 01/26/2012 | WO2012010291A1 Diagnostic and therapeutic methods and compositions for metabolic disease |
| 01/26/2012 | WO2012010290A1 Diagnostic and therapeutic methods and compositions for metabolic disease |
| 01/26/2012 | WO2011152689A9 Method for purifying fucoxanthin derived from seaweed |
| 01/26/2012 | WO2010144140A8 Egfr and par2 regulation of intestinal permeability |
| 01/26/2012 | US20120023600 Compositions and methods of use for antibodies of dickkopf-1 |
| 01/26/2012 | US20120022500 Compositions and Methods for Induced Brown Fat Differentiation |
| 01/26/2012 | US20120022167 Trans-Clomiphene for Metabolic Syndrome |
| 01/26/2012 | US20120022157 Dosing and monitoring patients on nitrogen-scavenging drugs |
| 01/26/2012 | US20120022154 N-hydroxy c29-amide derivatives of oleandrane |
| 01/26/2012 | US20120022139 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration |
| 01/26/2012 | US20120022138 Means for inhibiting the expression of ang2 |
| 01/26/2012 | US20120022133 Antisense modulation of cholesteryl ester transfer protein expression |
| 01/26/2012 | US20120022126 Method Of Treating Diabetes Mellitus |
| 01/26/2012 | US20120022116 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | US20120022092 Protein kinase c inhibitors and uses thereof |
| 01/26/2012 | US20120022086 Catecholamine derivatives for obesity and neurological disorders |
| 01/26/2012 | US20120022080 Plasminogen Activator Inhibitor-1 Inhibitor |
| 01/26/2012 | US20120022078 Aryl indole derivatives |
| 01/26/2012 | US20120022075 Novel phenylpyrrole derivative |
| 01/26/2012 | US20120022072 Pterin analogs |
| 01/26/2012 | US20120022064 Dihydroquinolinone derivatives |
| 01/26/2012 | US20120022058 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| 01/26/2012 | US20120022057 Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
| 01/26/2012 | US20120022052 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 01/26/2012 | US20120022039 Novel substituted indanes, method for the production thereof, and use thereof as drugs |
| 01/26/2012 | US20120022017 Composition and a method thereof |
| 01/26/2012 | US20120022007 Method and composition for modulating canonical wnt pathway using folate and inositol |
| 01/26/2012 | US20120021981 Compositions to prevent and treat type-1 diabetes |
| 01/26/2012 | US20120021980 Compositions for drug administration |
| 01/26/2012 | US20120021979 GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| 01/26/2012 | US20120021978 Combination of an insulin and a glp-1-agonist |
| 01/26/2012 | US20120021977 Promotion of healthy catch-up growth |
| 01/26/2012 | US20120021976 Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| 01/26/2012 | US20120021973 Peptides for Treatment of Obesity |
| 01/26/2012 | US20120021972 Peptidomimetics with glucagon antagonistic and glp 1 agonistic activities |
| 01/26/2012 | US20120021971 Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof |
| 01/26/2012 | US20120021970 Methods for preventing or treating mitochondrial permeability transition |
| 01/26/2012 | US20120021470 Chimeric PUFA Polyketide Synthase Systems and Uses Thereof |
| 01/26/2012 | US20120021079 Garcinia Mangostana L. and Iridoid Based Formulations |
| 01/26/2012 | US20120021067 Maintenance fluid for animals |
| 01/26/2012 | US20120021053 Controlled release and taste-masking oral pharmaceutical composition |
| 01/26/2012 | US20120021049 Single Daily Dosage Form for Prevention and Treatment of Metabolic Syndrome |
| 01/26/2012 | US20120021016 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120020982 Formulations and treatments for trichology |
| 01/26/2012 | US20120020975 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 01/26/2012 | US20120020974 Optimizing erythropoietin therapy |
| 01/26/2012 | US20120020963 Anti-inteferon alpha monoclonal antibodies and methods for use |
| 01/26/2012 | US20120020956 Activation of sodium potassium atpase |
| 01/26/2012 | US20120020944 Use of a probiotic to regulate body weight |
| 01/26/2012 | US20120020941 Use of blood group status iii |
| 01/26/2012 | US20120020936 Treatment of neurodegenerative disease using placental stem cells |
| 01/26/2012 | US20120020926 Composition comprising caftaric acid and/or derivatives thereof |
| 01/26/2012 | US20120020916 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases |
| 01/26/2012 | US20120020913 Methods for pancreatic tissue regeneration |
| 01/26/2012 | US20120020885 MHC-Less cells |
| 01/26/2012 | US20120017924 Coated nicotine-containing chewing gum, manufacture and use thereof |
| 01/26/2012 | CA2806271A1 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics |
| 01/26/2012 | CA2806258A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | CA2806221A1 Tricyclic compounds and methds of making and using same |
| 01/26/2012 | CA2805904A1 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| 01/26/2012 | CA2805745A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/25/2012 | EP2409713A1 Oligonucleotides for use in modulating lipoprotein and cholesterol levels in humans |
| 01/25/2012 | EP2409706A1 Dihydropteridinones for the treatment of cancer diseases |
| 01/25/2012 | EP2409698A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition |
| 01/25/2012 | EP2409696A1 Agent for promoting energy consumption |
| 01/25/2012 | EP2409569A2 Method for administering GLP-1 molecules |
| 01/25/2012 | EP2408774A2 Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
| 01/25/2012 | EP2408766A1 Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| 01/25/2012 | EP2408749A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/25/2012 | EP2408745A1 Piperidine derivatives as nk3 receptor antagonists |
| 01/25/2012 | EP2408744A1 Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| 01/25/2012 | EP2408468A2 USE OF NKp46 FOR PREVENTING DIABETES |
| 01/25/2012 | EP2408455A2 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders |
| 01/25/2012 | EP2408443A1 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| 01/25/2012 | EP2408441A1 Combination therapies for treating metabolic disorders |
| 01/25/2012 | EP2408434A1 Treating alzheimer's disease and osteoporosis and reducing aging |
| 01/25/2012 | EP2408318A1 Use of whole grain materials with high resistant starch for satiety, reduction of food intake and weight management |
| 01/25/2012 | EP2235011B1 Substituted pyrrolo[2, 3-b]and pyrazolo[3, 4-b]pyridines for use as adenosine receptor ligands |
| 01/25/2012 | EP2187926B1 Prevention of diabetes by administration of gliadin |
| 01/25/2012 | EP2100877B1 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 01/25/2012 | EP2049513B1 Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |